Secret Biopharms Growing
Frankencrops Across the US

Secret US 'biopharms' growing GM experimental drugs
WASHINGTON, DC, July 16, 2002 (ENS)

Experimental plants engineered to produce pharmaceuticals are being grown
at over 300 secret locations nationwide, a new report has revealed.
Biotechnology firms are conducting experiments with corn, soy, rice and
tobacco that are genetically manipulated to produce drugs designed to act
as vaccines, contraceptives, induce abortions, generate growth hormones,
create blood clots, produce industrial enzymes and propagate allergenic

"Just one mistake by a biotech company and we'll be eating other people's
prescription drugs in our corn flakes," said Larry Bohlen, director of
health and environment programs at Friends of the Earth, a member of a
coalition of consumer and environmental groups that produced the report,
released late last week. The experimental application of biotechnology in
which plants are genetically engineered to produce pharmaceutical proteins
and chemicals they do not produce naturally has been termed "biopharming."
Companies engaged in biopharming keep their activities secret, citing the
secret plantings as confidential business information.

The report, entitled "Manufacturing Drugs and Chemicals in Crops:
Biopharming Poses New Threats to Consumers, Farmers, Food Companies
and the Environment," was produced by the Genetically Engineered Food
Alert coalition and presented to Agriculture Secretary Ann Veneman on
Thursday. To date, the secretary has made no public comment on the report.
In a letter to Veneman, the coalition called for an end to open air cultivation
of crops engineered to produce prescription drugs or industrial chemicals.
"The USDA [U.S. Department of Agriculture] should prohibit the planting of
food crops engineered with drugs and chemicals to protect the food supply
from contamination," Bohlen said.

The highest number of field trials are taking place in Nebraska, Hawaii,
Wisconsin and Puerto Rico. But other states, including Iowa, Florida,
Illinois, Texas, California, Maryland, Kentucky and Indiana, also have
numerous tests being conducted near food producing farms. The report
details the many threats that biopharm crops pose, the extent to which
crops have been planted across the United States, the failure of regulatory
agencies to regulate the experiments, and a set of recommendations.

The coalition proposes that the USDA permit limited cultivation of non-food
plants in the same controlled environment as other drug production.
The USDA has primary authority for experimental biopharm crop cultivation.
Historically, the agency has kept all drug and chemical crop sites secret
from the public and neighboring farmers, and has hidden the identity of the
drugs or chemicals being produced. The agency has condoned companies'
preferred practice of anonymously planting biopharm crops without
identification, security measures or notification of neighbors, the report

Coalition members are concerned that genetically engineered traits could
spread from biopharms through pollen carried by wind or insects, spilled
seed, unharvested seed sprouting the next year, and biopharm seed residues
carried by farm equipment to conventional fields. "Current gene containment
strategies cannot work reliably in the field, the editors of the journal
"Nature Biotechnology" said. "Can we reasonably expect farmers to [clean]
their agricultural equipment meticulously enough to remove all GM seed?"
In response to the report, a National Academy of Sciences spokesperson who
preferred not to be identified, said, "It is possible that crops
transformed to produce pharmaceutical or other industrial compounds might
mate with plantations grown for human consumption, with the unanticipated
result of novel chemicals in the human food supply."

Biopharm companies normally contract with selected farmers to grow their
genetically engineered drug or chemical crops. The coalition contends that
when one field is sown, all farmers, through their proximity to the test
field, are exposed to substantial liability from the biopharming.
Neighboring farmers whose fields become contaminated with drug or chemical
traits have no choice but to file expensive lawsuits against the
biopharming companies.

On the other hand, biopharm companies that discover their patented drug
traits in conventional farmers' contaminated fields could sue those
farmers, alleging violation of the company's intellectual property rights.
The majority of engineered biopharmaceuticals and chemicals are
incorporated into corn, a prolific pollinator, followed by soybeans,
tobacco and rice. The engineered plants are then integrated into farmers'
fields where it is impossible to detect their presence. Contamination of
farmers' corn by engineered insecticides is already widespread. Iowa farmer
Laura Krouse said, "I've seen sales of open-pollinated corn drop 50-75
percent due to genetic pollution with engineered traits."

Corn is especially risky for pharmaceutical applications because it readily
cross-pollinates and its pollen can travel for miles. This has been
demonstrated by engineered StarLink corn, which contaminated food products
and corn seed stock with a potentially allergenic protein even while
companies were taking gene containment measures.

Nevertheless, two-thirds of open air biopharm field trials have been in
corn. Experts have warned that current isolation standards will not prevent
contamination of normal corn. According to the coalition's report,
engineered viruses used to infect plants with drug genes could easily
spread to related crops.

In response to one report of biopharm contamination, Chris Webster, a
representative of Pfizer Pharmaceuticals said, "We've seen, on the vaccine
side, where modified live seeds have wandered off and have appeared in
other products." ProdiGene, the company with the most plantings of drug and
chemical producing plants, projects that 10 percent of the U.S. corn crop
will be devoted to biopharm production by 2010.

Far from supporting containment strategies such as buffer areas,
ProdiGene's CEO Anthony Laos is pressing for their elimination. He wrote
farmers in 2001, "We will be dealing with these distances until we can gain
regulatory approval to lessen or abandon these requirements altogether."
Some companies propose extracting drugs or chemicals from plants, then
selling the remainder of the plant material. Incomplete extraction would
mean drug and chemical residue in food or feed.

"Farmers cannot afford another contamination incident hurting sales and
throwing the harvest into turmoil like StarLink did in 2000," said Matt
Rand, biotechnology campaign manager at the National Environmental Trust.
The report cites indications that standard methods of pharmaceutical
cultivation may be more cost effective and safer than open field testing.
Laboratories conventionally develop new drugs through extraction from
animal or human tissues or production in animal, bacterial and yeast cell
cultures. Newer techniques include plant cell cultures and secretion of
biopharm proteins from plant roots into hydroponic media.

In contrast to open air biopharming, these methods are contained to the
laboratory environment, greatly reducing contamination risks, the coalition
maintains. These practices allow complete control of growth conditions
where purification is easier, producing a more consistent drug quality.
The complete report is available online at:

Home | News | Organics | GE Food | Health | Environment | Food Safety | Fair Trade | Peace | Farm Issues | Politics
Español | Campaigns | Buying Guide | Press | Search | Donate | About Us | Contact Us

Organic Consumers Association - 6771 South Silver Hill Drive, Finland MN 55603
E-mail: Staff · Activist or Media Inquiries: 218-226-4164 · Fax: 218-353-7652
Please support our work. Send a tax-deductible donation to the OCA

Fair Use Notice: The material on this site is provided for educational and informational purposes. It may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. It is being made available in an effort to advance the understanding of scientific, environmental, economic, social justice and human rights issues etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have an interest in using the included information for research and educational purposes. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. The information on this site does not constitute legal or technical advice.